Less than three months after U.S. Senator Tammy Baldwin and her colleagues launched an investigation into the four major American manufacturers of inhalers, three of the companies have relented, making commitments to cap costs for their inhalers at $35 for patients who now pay much more.
25 million Americans have asthma and 16 million Americans have chronic obstructive pulmonary disease (COPD), meaning over 40 million Americans rely on inhalers to breathe.
Inhalers have been available since the 1950s, and most of the drugs they use have been on the market for more than 25 years.
According to a statement from the Wisconsin Senator’s office, inhaler manufacturers sell the exact same products at a much lower costs in other countries. One of AstraZeneca’s inhalers, Breztri Aerosphere, costs $645 in the U.S.—but just $49 in the UK. Inhalers made by Boehringer Ingelheim, GlaxoSmithKline, and Teva have similar disparities.
Baldwin and her Democratic colleagues—New Mexico Sen. Ben Ray Luján, Massachusetts Sen. Ed Markey, and Vermont Sen. Bernie Sanders—pressured the companies to lower their prices by writing letters to GSK, Boehringer Ingelheim, Teva, and AstraZeneca requesting a variety of documents that show why such higher prices are charged in America compared to Europe.
As a ranking member of the Senate Committee on Health, Education, Labor, and Pensions, Baldwin recently announced that as a result of the letters they had secured commitments from three of the four to lower the out-of-pocket costs of inhalers to a fixed $35.00 rate.
REGULATORY NEWS: US Sets Policy to Seize U.S. Patents of Government-Funded Drugs if Price Deemed Too High
“For the millions of Americans who rely on inhalers to breathe, this news is a major step in the right direction as we work to lower costs and hold big drug companies accountable,” said Senator Baldwin.
MORE GOOD NEWS LIKE THIS: Drugs From Mark Cuban’s Pharmacy Could Save Medicare Billions Every Year, Harvard Says
A full list of the inhalers and associated drugs can be viewed here.
It’s the second time in the last year that pharmaceutical companies were forced to provide reasonable prices—after the cost of insulin was similarly capped successfully at $35 per month thanks to Congressional actions led by the White House.
SHARE This Amazing Good News With Any Asthmatics You Know…
